| In millions, except per share items | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Interest income: |
| Interest income on loans | 23.1 | 18.7 | 16.8 | 15.6 | 16.2 | 16.3 | 16.3 | 16.6 |
| Interest income on investments | 4.0 | 2.5 | 1.9 | 1.7 | 1.5 | 1.3 | 1.1 | 1.1 |
| | 27.3 | 21.3 | 18.8 | 17.3 | 17.8 | 17.7 | 17.4 | 17.7 |
| Interest expense: |
| Interest on deposits | 6.7 | 1.9 | 0.8 | 0.5 | 0.6 | 0.6 | 0.6 | 0.8 |
| | 8.2 | 2.3 | 1.2 | 0.9 | 0.9 | 1.1 | 1.0 | 1.2 |
| Net interest income | 19.1 | 19.1 | 17.6 | 16.5 | 16.9 | 16.6 | 16.4 | 16.5 |
| Provision for loan losses | 0.7 | 0.7 | 0.4 | 0.5 | 0.1 | | 0.2 | 0.3 |
| Net interest income after provision for loan losses | 18.4 | 18.4 | 17.1 | 16.0 | 16.8 | 16.6 | 16.2 | 16.2 |
| Other non-interest income | 1.4 | 1.2 | 1.4 | 1.5 | 2.3 | 1.4 | 1.9 | 2.4 |
| Total non-interest income | 1.4 | 1.2 | 1.4 | 1.5 | 2.3 | 1.4 | 1.9 | 2.4 |
| Non-interest expenses | 10.2 | 9.6 | 9.3 | 9.1 | 10.2 | 9.4 | 9.4 | 10.1 |
| Pre-tax income before non-recurring items | 10.0 | 10.0 | 9.2 | 8.5 | 8.4 | 8.7 | 8.5 | 10.3 |
| Non-recurring items | 0.3 | 0.0 | 0.0 | 0.0 | -0.6 | 0.1 | -0.1 | 1.9 |
| Pre-tax income | 9.7 | 10.0 | 9.2 | 8.4 | 9.0 | 8.6 | 8.6 | 8.4 |
| Income taxes | 2.4 | 2.4 | 2.4 | 2.1 | 2.2 | 2.2 | 2.2 | 2.1 |
| Tax rate | 24.4% | 23.9% | 25.7% | 25.3% | 24.9% | 25.2% | 25.4% | 25.2% |
| Net income | 7.3 | 7.6 | 6.8 | 6.3 | 6.8 | 6.4 | 6.4 | 6.3 |
| Net margin | 36.9% | 38.7% | 36.8% | 36.0% | 35.3% | 35.6% | 35.6% | 33.9% |
| |
| Basic EPS | $1.30 | $1.34 | $1.21 | $1.11 | $1.17 | $1.12 | $1.10 | $1.07 |
| Diluted EPS | $1.30 | $1.34 | $1.21 | $1.10 | $1.16 | $1.12 | $1.10 | $1.07 |
| |
| Shares outstanding (basic) | 5.7 | 5.6 | 5.6 | 5.7 | 5.8 | 5.7 | 5.8 | 5.9 |
| Shares outstanding (diluted) | 5.7 | 5.6 | 5.7 | 5.7 | 5.8 | 5.7 | 5.9 | 5.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |